Answers are grounded in this paper and cite their sources.
Background: Smokeless tobacco (SLT) dependence is a pervasive public health burden across South Asia, driving high rates of oral potentially malignant disorders and cardiovascular morbidity. Conventional nicotine replacement and pharmacotherapeutic regimens show modest long-term abstinence rates in SLT chewers. Although classical homoeopathic literature describes several remedies for the constitutional and toxicological effects of tobacco, prospective clinical data evaluating individualized prescriptions remain sparse. Objectives: To evaluate the clinical effectiveness of individualized homoeopathic medicines in reducing physical nicotine dependence, subjective craving intensity, oral-health-related quality of life impairment, and daily chewing frequency among chronic smokeless tobacco users over a 6-month follow-up period. Methods: A prospective, single-blind, interventional clinical study was conducted on 100 adult smokeless tobacco users (aged 20–60 years; baseline FTND-ST score ≥ 4) at the outpatient department of Prayas Nasha-Mukti Evam Manochikitsa Kendra, Bhopal, India. Following detailed case-taking and repertorization using the Complete Repertory in CARA software, patients received one of eleven individualized homoeopathic remedies, with interspersed Sacchrum lactis (Rubrum) placebo phases to preserve single-blinding. Prescriptions distributed in descending order of clinical frequency were Arsenicum album (n = 16), Cinchona officinalis [China] (n = 14), Nux vomica (n = 13), Tabacum (n = 11), Ignatia amara (n = 10), Staphysagria (n = 9), Natrum carbonicum (n = 8), Caladium seguinum (n = 7), Erythroxylum coca (n = 5), Phosphorus (n = 4), and Spigelia anthelmia (n = 3). Outcomes were assessed at baseline and 6 months using the Fagerström Test for Nicotine Dependence–Smokeless Tobacco (FTND-ST), Oral Health Impact Profile (OHIP-18), Daily Tobacco Consumption Frequency (sessions/day), and a 0–10 Subjective Craving Visual Analogue Scale. Results: At the 6-month endpoint, statistically significant reductions were observed across the cohort (N = 100) in FTND-ST scores (6.01 ± 1.99 to 4.38 ± 2.68; mean reduction: 1.63 ± 2.07; Wilcoxon p < 0.001; d = 0.79, r = 0.45), OHIP-18 scores (baseline: 25.14 ± 8.77 vs. 6 months: 20.45 ± 9.99; mean reduction: 4.69 ± 4.17; t = 11.24, p < 0.001; Cohen’s d = 1.12), and subjective craving intensity (7.35 ± 1.84 to 5.89 ± 2.95; mean reduction: 1.46 ± 2.58; Wilcoxon p < 0.001; d = 0.57, r = 0.35). Daily chewing frequency declined from 15.10 ± 5.07 to 14.17 ± 7.09 sessions/day (mean difference: 0.93 ± 4.99; paired t-test p = 0.065; d = 0.19). Subgroup analysis demonstrated distinct clinical profiles: Ignatia amara (Δ = 6.00 ± 4.19, p = 0.001), China (Δ = 5.79 ± 4.58, p = 0.004), Staphysagria (Δ = 5.78 ± 4.66, p = 0.006), and Arsenicum album (Δ = 5.25 ± 3.04, p < 0.001) produced pronounced improvements in oral quality of life and dependence, whereas Tabacum (n = 11) achieved the most marked reduction in daily chewing sessions (Δ = 3.73 ± 4.38, p = 0.008, d = 0.85).
No takes yet. Share an insight, caveat, or question.
Tiwari et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: